retatrutide phase 2 trial new england journal of medicine Availability & Timeline Retatrutide, a GIP, GLP-1 and

In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]

- TRIUMPH-4: Stand-alone knee osteoarthritis trial

You would never know it happened by looking at the vial

[13] [14] These risks are discussed further in the red-flag section below

Nausea & digestive issues The medication causes nausea that can make the muscles of your head and neck tight, which may lead to headache

What's the difference between GLP-1 supplements and GLP-1 support supplements